Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2023 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
ELVN on Nasdaq
Shares outstanding
59,746,870
Price per share
$25.75
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,780,703
Total reported value
$258,426,289
% of total 13F portfolios
0%
Share change
+368,520
Value change
-$1,247,286
Number of holders
76
Price from insider filings
$25.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
FMR LLC 13% $161,103,383 7,870,219 FMR LLC 30 Sep 2025
Commodore Capital LP 9.9% $135,215,385 6,022,957 Commodore Capital LP 30 Jun 2025
Fairmount Funds Management LLC 6.3% -4.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66,042,996 3,226,331 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
BlackRock, Inc. 5.1% $59,005,266 2,941,395 BlackRock, Inc. 30 Jun 2025
Polar Capital Holdings Plc 5.2% +5.6% $56,952,978 +$3,304,932 2,536,881 +6.2% Polar Capital Holdings Plc 30 Jun 2025

As of 31 Dec 2025, 76 institutional investors reported holding 16,780,703 shares of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN). This represents 28% of the company’s total 59,746,870 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6% 3,613,326 +2.7% 0% $55,645,219
VANGUARD GROUP INC 4.7% 2,801,665 +9.7% 0% $43,145,640
Capital Research Global Investors 2.2% 1,304,346 -0.85% 0% $20,086,928
Pictet Asset Management Holding SA 2.2% 1,303,235 -6.8% 0.02% $20,069,819
STATE STREET CORP 1.8% 1,052,862 +9.1% 0% $16,214,075
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,048,722 -3.3% 0% $16,153,779
Soleus Capital Management, L.P. 1.7% 1,025,000 0.67% $15,785,000
Candriam S.C.A. 0.76% 453,019 -26% 0.03% $6,976,790
Spruce Street Capital LP 0.75% 446,084 0% 2.3% $6,869,694
MORGAN STANLEY 0.69% 411,823 +59% 0% $6,342,080
DIMENSIONAL FUND ADVISORS LP 0.67% 398,893 +149% 0% $6,143,418
MARSHALL WACE, LLP 0.62% 371,906 +9.2% 0.01% $5,727,353
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.59% 355,192 -2.2% 0% $5,469,957
Patient Square Capital LP 0.52% 308,141 +23% 1% $4,745,371
GOLDMAN SACHS GROUP INC 0.4% 237,204 -9.6% 0% $3,652,941
Exome Asset Management LLC 0.37% 222,308 1.7% $3,423,543
Connor, Clark & Lunn Investment Management Ltd. 0.33% 194,735 +460% 0.01% $2,998,919
Avidity Partners Management LP 0.23% 140,300 0% 0.62% $2,160,620
Bank of New York Mellon Corp 0.19% 110,569 -4.4% 0% $1,702,762
Nuveen, LLC 0.18% 105,448 -2.6% 0% $1,623,899
JANE STREET GROUP, LLC 0.17% 101,971 0% $1,570,353
BARCLAYS PLC 0.12% 69,875 -1.2% 0% $1,076,074
Swiss National Bank 0.11% 64,273 +1.7% 0% $989,804
UBS Group AG 0.1% 57,868 -27% 0% $891,167
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.09% 55,210 +6.8% 0% $850,234

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,780,703 $258,426,289 -$1,247,286 $15.40 76
2025 Q3 59,389,507 $1,215,687,864 -$296,038 $20.47 132
2025 Q2 59,434,902 $1,192,251,085 +$192,194,924 $20.06 123
2025 Q1 49,886,849 $983,923,667 +$4,352,699 $19.68 118
2024 Q4 49,624,914 $1,116,597,658 +$24,828,957 $22.50 111
2024 Q3 47,688,348 $1,218,010,157 -$20,810,259 $25.54 100
2024 Q2 48,318,843 $1,129,194,355 +$91,652,714 $23.37 91
2024 Q1 44,456,336 $780,753,492 +$95,045,035 $17.59 72
2023 Q4 39,000,634 $539,791,932 -$652,659 $13.84 61
2023 Q3 39,076,502 $533,779,750 -$2,178,662 $13.66 60
2023 Q2 39,092,843 $797,915,923 +$112,876,379 $20.41 61
2023 Q1 33,557,749 $734,910,999 +$734,911,000 $21.90 44